BIOMAT Database Logo BIOMAT Database Logo

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. 1997

J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Cambridge University Department of Pathology, UK.

We have investigated the biological and therapeutic properties of a humanized anti-CD4 MoAb, hIgG1-CD4, in patients with refractory psoriasis and rheumatoid arthritis (RA). hIgG1-CD4 is a modulating, non-depleting MoAb, which induced a first-dose reaction in most patients treated. It provided brief symptomatic relief in both conditions, and psoriasis appeared easier to control with conventional agents after MoAb therapy. At the doses used, hIgG1-CD4 did not synergize therapeutically with the panlymphocyte MoAb CAMPATH-1H (C1H) in patients with RA treated sequentially with both agents. There were no serious adverse effects definitely attributable to therapy. Our results are compared with those of other CD4 MoAb studies, and factors influencing the outcome of therapy are discussed.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Anti-CD4 monoclonal antibody therapy in human autoimmune diseases.
January 2000, Current directions in autoimmunity,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Anti-CD4 monoclonal antibody therapy.
October 1996, Clinical transplantation,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice.
May 1992, Cellular immunology,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody.
August 1991, Lancet (London, England),
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases.
January 1997, Clinical and experimental rheumatology,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.
February 1998, The Journal of rheumatology,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease.
January 1987, Ciba Foundation symposium,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Anti-CD4 monoclonal antibody therapy in severe psoriasis.
August 1992, Journal of autoimmunity,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Treatment of autoimmune disease with monoclonal anti-CD4 antibodies.
January 1989, Immunology series,
J D Isaacs, and N Burrows, and M Wing, and M T Keogan, and P R Rebello, and R A Watts, and R J Pye, and P Norris, and B L Hazelman, and G Hale, and H Waldmann
Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody.
December 1987, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!